Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation1

Neoplasia

Volumn 11, Issue 4, 2009, Pages 408-417

  Asada, Masanori ^a   Ebihara, Satoru ^a   Yamanda, Shinsuke ^a   Niu, Kaijun ^a   Okazaki, Tatsuma ^a   Sora, Ichiro ^a,b   Arai, Hiroyuki ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Department of Medicine ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (1 METHYL 5 INDOLYL) N (3 METHYL 5 ISOTHIAZOLYL)UREA; PHOSPHOSPECIFIC ANTIBODY; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOREBRAIN; IN VITRO STUDY; KNOCKOUT MOUSE; LEWIS CARCINOMA; MALE; MELANOMA CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEROTONIN BLOOD LEVEL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; TUMOR GROWTH; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; ANIMAL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RECEPTOR, SEROTONIN, 5-HT2B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; UMBILICAL VEINS;

EID: 65549134709     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81.630     Document Type: Article

References (48)

1. Nakaya N, Tsubono Y, Hosokawa T, Nishino Y, Ohkubo T, Hozawa A, Shibuya D, Fukudo S, Fukao A, Tsuji I, et al. (2003). Personality and the risk of cancer. J Natl Cancer Inst 95, 799-805. (Pubitemid 36798426)
2. Asada M, Ebihara S, Okazaki T, Takahashi H, Yasuda H, and Sasaki H (2005). Tiapride may accelerate lung cancer in older people: a case report. J Am Geriatr Soc 53, 731-732. (Pubitemid 41623503)
3. Asada M, Ebihara S, Numachi Y, Okazaki T, Yamanda S, Ikeda K, Yasuda H, Sora I, and. Arai H (2008). Reduced tumor growth in a mouse model of schizo- phrenia, lacking the dopamine transponer. Int J Cancer 123, 511-518.
4. Cattaneo MG, Codignola A, Vicentini LM, Clementi F, and Sher E (1993). Nicotine stimulates a serotonergic autocrine loop in human small-cell lung car- cinoma. Cancer Res 53, 5566-5568. (Pubitemid 23342185)
5. Cattaneo MG, Fesce R, and Vicentini LM (1995). Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HTIA and 5-HT1D recep- tors. Eur J Pharmacol 291, 209-211.
6. Vicaut E, Laemmel E, and. Stucker O (2000). Impact of serotonin on tumour growth. Ann Med 32, 187-194. (Pubitemid 30237564)
7. Siddiqui EJ, Thompson CS, Mikhailidis DP, and Mumtaz FH (2005). The role of serotonin in tumour growth [Review]. Oncol Rep 14, 1593-1597.
8. Hoyer D, Hannon JP, and Martin GR (2002). Molecular, pharmacologi- cal and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71, 533-554. (Pubitemid 34219205)
9. Sheehan PF, Baker T, Tutton PJ, and Barkla DH (1996). Effects of histamine and 5-hydroxytryptamine on the growth rate of xenografted human bronchogenic cardnomas. Clin Exp Pharmacol Physiol 23, 465-471. (Pubitemid 26186424)
10. Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, and Ushijima T (2001). Silencing of HTRlB and reduced expression of EDNl in human lung cancers, revealed by methylation-sensitive representational difference analy- sis. Oncogene 20, 7505-751.3. (Pubitemid 33086910)
11. Dizeyi N, Bjartell A, Hedlund P Tasken KA, Gadaleanu V, and Abrahamsson PA (2005). Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and. effects of their antagonists on prostate cancer cell lines. Eur Urol 47, 895-900. (Pubitemid 40745366)
12. Bonhaus DW, Bach. C, DeSouzaA, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, and Eglen RM (1995). The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115, 622-628.
13. Choi DS and Maroteaux. L (1996). Immunohistochemical localisation of the serotonin 5-HT28 receptor in mouse gut, cardiovascular system, and brain. FEBS Lett 391, 45-51. (Pubitemid 26325711)
14. Duxon MS, Kennett GA, Lightowler S, Blackburn TP, and Fone KC (1997). Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 36, 601-608. (Pubitemid 27272105)
15. Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP and Fone KC (1997). Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neurosdence 76, 323-329. (Pubitemid 27008463)
16. Borman RA and Burleigh DE (1997). 5-HT, D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine. Ann N Y Acad Sei 812, 222-223. (Pubitemid 27309720)
17. Lauder JM, Wilkie MB, Wu C, and Singh S (2000). Expression of 5-HT (2A), 5-HT (2B) and 5-HT (2C) receptora in the mouse embryo. Int J Dev Neurosa 18, 653-662. (Pubitemid 30649687)
18. Tutton PJ and Steel GG (1979). Influence of biogenic amines on the growth of xenografted human colorectal carcinomas. BrJ Cancer 40, 743-749. (Pubitemid 10204793)
19. Palmer RMJ, Ferrige AG, and Moneada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526. (Pubitemid 17085822)
20. Ullmer C, Schmuck K, Kalkman HO, and Lubbert H (1995). Expression of serotonin receptor mRNAs in bloodvessels. FEBSLett370, 215-221.
21. Glusa E and. Roos A (1996). Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine. Br J Pharmacol 119, 330-334. (Pubitemid 26326467)
22. Johnson KW, Phebus LA, and Cohen ML (1998). Serotonin in migraine: theo- ries, animal models and emerging therapies. Prog Drug Res 51, 219-244. (Pubitemid 28511545)
23. Brian JE Jr and Kennedy RH (1993). Modulation of cerebral arterial tone by endothelium-derived relaxing factor. Am J Physiol 264, H1245-H1250. (Pubitemid 23115300)
24. Cappelli-Bigazzi M, Nu.no DW, and Lamping KG (1991). Evidence of a role for compounds derived from arginine in coronary response to serotonin in vivo. AmJ Physiol 261, H404-H409.
25. McDuffle JE, Coaxum SD, and Maleque MA (1999). 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proc Soc Exp Biol Med 221, 386-390. (Pubitemid 29386027)
26. LaIa PK and. Orucevic A (1998). Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 7, 91-106. (Pubitemid 28194648)
27. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605. (Pubitemid 29279182)
28. Veenstra-VanderWeele J, Anderson GM, and Cook EH Jr (2000). Pharmaco- genetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 410, 165-181. (Pubitemid 32008142)
29. Erspamer V (1966). Occurrence of ¡ndolealkylamines in nature. In Erspamer V (Ed.). Handbook of Experimental Pharmacology: 5-Hydroxytryptamine and Related !ndolealkylamines. New York, NY: Springer-Verlag, 19, pp. 132-181.
30. Toh CC (1954). Release of 5-hydroxytryptam.ine (serotonin) from the dog's gastro- intestinal, tract. J. Physiol (Land) 126, 248-254.
31. Morrissey JJ, Walker MN, and Lovenberg W (1977). The absence of tryptophan hydroxylase activity in blood platelets. Proc Soc Exp Biol Med 154, 496-499. (Pubitemid 8106245)
32. Tamir H, Payette RF, Huang YL, Liu KP and Gershon MD (1985). Human serotonectin: a blood glycoprotein that binds serotonin, and is associated with platelets and white blood cells. J. Cell Sei 73, 187-206. (Pubitemid 15055070)
33. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, and Gershon MD (2001). Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal, motility and the expression, of cation transporters. J. Neurosa 21, 6348-6361. (Pubitemid 32737766)
34. Xu W, Tamim H, Shapiro S, Stang MR, and Collet JP (2006). Use of anti- depressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 7, 301-308.
35. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, Wichems C, Lesch KP Murphy DL, and UhI GR (2001). Molecular mechanisms of cocaine reward: combined, dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sd USA 98, 5300-5305. (Pubitemid 32397123)
36. Okazaki T, Ebihara S, Takahashi H, Asada M, Kanda A, and Sasaki H (2005). Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skelet al. muscle and promotes tumor angiogenesis. J Immunol 174, 7531-7538. (Pubitemid 40806256)
37. Verheggen R, Meier A, Werner I, Wienekamp A, Kruschat T, Brattelid T, Levy FO, and Kaumann A (2004). Functional 5-HT receptors in human occipital artery. Naunyn Schmiedebergs Arch Pharmacol 369, 391-401.
38. Seretis E, Gavrill A, Agnantis N, Gol.em.atis V, and Voloudakis-Baltatzis IE (2001). Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumors of the colon. Ultrastruct Pathol 25, 445-454.
39. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, and Arai H (2008). Erythropoietin promotes the growth, of tumors lacking its receptor and de- creases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10, 932-939.
40. Tutton PJ and Barkla DH (1982). Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. BrJ Cancer 46, 260-265. (Pubitemid 12053078)
41. Cowen DS (2007). Serotonin and neuronal growth factors-a convergence of sig- naling pathways. J. Neurochem 101, 1161-1171. (Pubitemid 46718809)
42. Shaul PW (2002). Regulation of endothelial nitric oxide synthase: location, loca- tion, location. Annu Rev Physiol 64, 749-774. (Pubitemid 34259248)
43. Rosetti M, Frasnelli M, Tesei A, ZoIi W, and Conti M (2006). Cytotoxicity of diffèrent selective serotonin reuptake inhibitors (SSRIs) against cancer cells./.Exp Ther Oncol 6, 23-29. (Pubitemid 46068190)
44. Kremer HP Goekoop JG, and Van Kempen. GM (1990). Clinical use of the determination of serotonin in whole blood. J. Clin Psychopharmacol 10, 83-87. (Pubitemid 20137603)
45. McDuffie JE, Motley ED, Limbird LE, and Maleque MA (2000). 5-Hydroxy- tryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation, in bovine aortic endothelial, cell cultures. J. Cardiovasc Pharmacol 35, 398-402. (Pubitemid 30127186)
46. Schmuck K, Ullmer C, Kalkman HO, Probst A, and Lubbert H (1996). Activa- tion of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosa 6, 959-967. (Pubitemid 26148358)
47. Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, and Baxter GS (2002). 5-HT (2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. BrJ Pharmacol 135, 1144-1151. (Pubitemid 34259114)
48. McLean PG, Borman RA, and Lee K (2007). 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 30, 9-13. (Pubitemid 46001679)